Combination regimen shows promising results in preclinical models of triple negative

[News]

Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.

More... (https://www.news-medical.net/news/20191210/Combination-regimen-shows-promising-results-in-preclinical-models-of-triple-negative-breast-cancer.aspx)